KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Capital Expenditures (2017 - 2025)

Aquestive Therapeutics has reported Capital Expenditures over the past 9 years, most recently at -$425000.0 for Q4 2025.

  • Quarterly results put Capital Expenditures at -$425000.0 for Q4 2025, down 543.94% from a year ago — trailing twelve months through Dec 2025 was $52000.0 (down 33.33% YoY), and the annual figure for FY2025 was $52000.0, down 33.33%.
  • Capital Expenditures for Q4 2025 was -$425000.0 at Aquestive Therapeutics, down from $235000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for AQST hit a ceiling of $826000.0 in Q2 2023 and a floor of -$425000.0 in Q4 2025.
  • Median Capital Expenditures over the past 5 years was $103500.0 (2021), compared with a mean of $153100.0.
  • Biggest five-year swings in Capital Expenditures: soared 1350.0% in 2024 and later crashed 543.94% in 2025.
  • Aquestive Therapeutics' Capital Expenditures stood at $533000.0 in 2021, then crashed by 95.12% to $26000.0 in 2022, then crashed by 38.46% to $16000.0 in 2023, then tumbled by 512.5% to -$66000.0 in 2024, then crashed by 543.94% to -$425000.0 in 2025.
  • The last three reported values for Capital Expenditures were -$425000.0 (Q4 2025), $235000.0 (Q3 2025), and $107000.0 (Q2 2025) per Business Quant data.